Dynamic monitoring of circulating microRNAs as a predictive biomarker for the diagnosis and recurrence of papillary thyroid carcinoma.
Dynamic monitoring of circulating microRNAs as a predictive biomarker for the diagnosis and recurrence of papillary thyroid carcinoma.
复制标题
动态监测循环 microRNA 作为甲状腺乳头状癌诊断和复发的预测生物标志物
DOI：
10.3892/ol.2017.6028
复制
发表时间：
2017-06
期刊：
影响因子：
2.9
通讯作者：
Qiao H
中科院分区：
文献类型：
--
作者：
Zhang Y;Xu D;Pan J;Yang Z;Chen M;Han J;Zhang S;Sun L;Qiao H
循环microRNA（miRNAs/miRs）被认为是许多类型癌症的潜在生物标志物。然而，以前的研究对甲状腺乳头状癌（PTC）患者血清中miRNAs的表达，以预测诊断，预后和复发的报道相互矛盾的结果，miRNAs的作用仍然不清楚。本研究动态评估了PTC患者的循环miRNA谱，并确定血清中的miRNA是否可用作PTC诊断、预后和复发的生物标志物。采用逆转录-定量聚合酶链反应分析了106例PTC患者、35例良性甲状腺结节（BTN）患者和40例配对对照中3种报告上调的miRNA（miR-222、miR-221和miR-146 b）的表达水平。招募接受甲状腺切除术的新诊断PTC或BTN患者，对术前和术后血清miRNA水平进行动态分析。结果表明，与对照组和BTN患者相比，新诊断PTC患者血清中miR-222、miR-221和miR-146 b的表达水平显著升高。受试者工作特征曲线分析表明，这些miRNAs对PTC术前诊断具有较高的敏感性和特异性。血清中这三种miRNAs的表达与甲状腺外浸润、淋巴结转移和高危或晚期肿瘤淋巴结转移阶段等预后较差的变量显著相关。更值得注意的是，本研究发现，在接受甲状腺切除术的患者之后，miR-222、miR-221和miR-146 b的血清水平分别降低了2.36倍、2.69倍和5.39倍。复发组miR-222、miR-221和miR-146 b的表达高于无复发组。总的来说，循环miRNA的动态监测可以作为PTC诊断和术后监测其进展和复发的非侵入性生物标志物。
Circulating microRNAs (miRNAs/miRs) are considered to be potential biomarkers for numerous types of cancer. However, previous investigations into the expression of miRNAs in the serum of patients with papillary thyroid carcinoma (PTC) to predict diagnosis, prognosis and recurrence have reported conflicting results, and the role of miRNAs remains unclear. The present study dynamically assessed the circulating miRNA profile in patients with PTC and determined whether miRNAs in the serum could be used as biomarkers for the diagnosis, prognosis and recurrence of PTC. The expression levels of 3 reportedly upregulated miRNAs (miR-222, miR-221 and miR-146b) were analyzed using reverse transcription-quantitative polymerase chain reaction in 106 patients with PTC, 35 patients with benign thyroid nodules (BTN) and 40 paired controls. Patients with either newly diagnosed PTC or BTN who were undergoing thyroidectomies were recruited for a dynamic analysis of preoperative and postoperative serum miRNA levels. The results indicated that the expression levels of serum miR-222, miR-221 and miR-146b were significantly increased in patients with newly diagnosed PTC compared with controls and patients with BTN. Receiver operating characteristic curve analysis indicated that these miRNAs had a high diagnostic sensitivity and specificity for PTC prior to surgery. The expression of these three miRNAs in serum was significantly associated with poorer prognostic variables, including extrathyroidal invasion, metastatic lymph nodes and high-risk or advanced tumor node metastasis stage. More notably, the present study identified 2.36-, 2.69- and 5.39-fold reductions in the serum levels of miR-222, miR-221 and miR-146b, respectively, subsequent to patients undergoing a thyroidectomy. In addition, miR-222, miR-221 and miR-146b were overexpressed in the PTC with recurrence group compared with the PTC without recurrence group. Collectively, dynamic monitoring of circulating miRNAs may serve as a non-invasive biomarker for the diagnosis of PTC and the postoperative monitoring of its progression and recurrence.